The Urology Group Introduces CyberKnife® SBRT System for Prostate Cancer
Exclusive regional provider of new high tech treatment
Cincinnati, Ohio [October 29, 2013] – The Urology Group introduces a new and advanced radiation treatment for prostate cancer patients across greater Cincinnati with the launch of the CyberKnife® stereotactic body radiation therapy (SBRT) system. The Urology Group is the only provider of this advanced technology in the region exclusively focused on prostate cancer.
Despite its name, CyberKnife SBRT involves no cutting and offers a non-invasive treatment option for many patients, delivering high doses of radiation with extreme accuracy through fewer treatments. Treatments will be conducted at The Urology Group’s main campus at 2000 Joseph E. Sanker Boulevard in Norwood.
The CyberKnife SBRT system features a robotic arm that provides both flexibility and precision. Pencil thin beams can be directed from potentially thousands of different angles, allowing a high dose of radiation to bombard cancerous cells with great accuracy while minimizing exposure to healthy neighboring tissues.
In addition, CyberKnife SBRT’s unique technology can detect prostate motion during treatment, which can occur naturally but without warning. When movement is detected, the CyberKnife robot corrects the aim of the radiation beam to help ensure accuracy and maximize the beneficial impact of the treatment.
CyberKnife SBRT offers significant advantages in patient convenience and comfort. Treatments can be completed in only five sessions, while other radiation treatments may require up to 40. In addition, the treatments can be completed without anesthesia or the use of a urinary catheter, and are performed as brief outpatient procedures.
“We are pleased to offer this exciting new technology to prostate cancer patients,” said Gary Kirsh, president of The Urology Group. “As the only center in the nation using CyberKnife SBRT exclusively for prostate cancer, our singular focus means our team of physicians and staff is specialized to deliver the best possible treatment for prostate cancer patients.”